StrideBio creates and develops adeno-associated viral (AAV) vector technologies and therapeutics that enables gene addition, gene silencing, and gene editing modalities for rare diseases. The Company develops a proprietary platform by combining structural information with accelerated evolution to create novel AAV capsids that can evade neutralizing antibodies.